Related Experiment Video
Updated: Sep 11, 2025
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
Antibodies against SARS-CoV-2 in children and adolescents: a one-year longitudinal study
Luciana de Freitas Velloso Monte1,2, Ana Luiza Rosa Diniz3,2, Cristiane Feitosa Salviano3
1Hospital da Criança de Brasília José Alencar, Brasília, Brazil luciana_fvm@yahoo.com.br.
Insights
Most children infected with SARS-CoV-2 maintain antibody responses for over a year, even with asymptomatic infection or comorbidities. Severe COVID-19 cases showed higher antibody levels at one year.
Area of Science:
- Immunology
- Virology
- Pediatrics
Background:
- The humoral immune response to SARS-CoV-2 in children remains incompletely understood.
- Investigating antibody durability in pediatric populations after natural infection is crucial.
Purpose of the Study:
- To analyze the antibody response to SARS-CoV-2 in children (0-18 years) during infection and over a 1-year follow-up.
- To assess the durability of adaptive immunity in unvaccinated, naturally infected pediatric patients.
Main Methods:
- A prospective, 1-year cohort study involving hospitalized children and adolescents with SARS-CoV-2 infection.
- Collection of clinical and serological data during infection and throughout the subsequent year.
Main Results:
- 85% of patients showed reactive antibodies throughout the 1-year follow-up.
- Detectable serum antibodies persisted in 72.46% of assessed individuals after 1 year.
- Antibody titers peaked around 60 days post-infection; lower levels were observed in patients with comorbidities.
Conclusions:
- Most pediatric subjects maintain SARS-CoV-2 antibody responses for over a year, irrespective of asymptomatic infection or comorbidities.
- Antibody response magnitude and duration varied, being lower in those with comorbidities and higher/longer in severe COVID-19 cases.
Background:
The humoral response to SARS-CoV-2 is not fully understood, especially in children. This study provides valuable insights into the durability of adaptive immunity in paediatric patients who were unvaccinated and naturally infected with the prototype strain of SARS-CoV-2, including those who were asymptomatic or had pre-existing chronic and rare disorders. This study aimed to analyse the antibody response to SARS-CoV-2 during infection and over a 1-year follow-up period in patients aged 0-18 years who were admitted to a tertiary paediatric hospital at the onset of the COVID-19 pandemic.
Methods:
This is a descriptive, prospective 1-year cohort study carried out in children and adolescents hospitalised for different reasons from July to October 2020 who presented with SARS-CoV-2 infection. Clinical and serological data (total antibody pool) were collected during SARS-CoV-2 infection and throughout the subsequent year.
Results:
During the study period, 122 patients with confirmed SARS-CoV-2 infection were included. Most patients (85%) had at least one serology assessed and reactive throughout 1-year follow-up, even those with asymptomatic infection or immunosuppressive conditions. The mean antibody titre levels reached their maximum value about 60 days after the initial SARS-CoV-2 infection. By the end of the 1-year follow-up, 72.46% of the 69 assessed individuals still had detectable serum antibodies. Patients with comorbidities and/or immunosuppression conditions had lower median titre levels over the year. Subjects with severe clinical presentation of COVID-19 had higher levels of antibody values at the 1-year time point assessment.
Conclusions:
This study demonstrated that most subjects presented antibody response against SARS-CoV-2 over 1 year of follow-up, even if they had asymptomatic infection or comorbidities, including patients with immunosuppression. There was a difference in the magnitude and duration of antibody response, lower in patients with comorbidities and longer and higher in subjects who had severe COVID-19 clinical presentation.
More Related Videos
10:25Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
07:08A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System
Published on: April 6, 2021
